Status In progress
Process STA
ID number 866

Provisional Schedule

Expected publication 22 August 2018

Project Team

Project lead Jeremy Powell

Email enquiries


Key events during the development of the guidance:

Date Update
13 October 2016 The technology appraisal of padeliporfin for treating localised prostate cancer (ID866) has been delayed at the request of Steba. NICE has agreed to this request because administration of the padeliporfin requires equipment that is currently not available in the NHS. NICE and Steba are exploring how this can be addressed.
02 June 2016 Draft scope documents
13 May 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance